-
Something wrong with this record ?
Antibiotic depot system with radiofrequency controlled drug release
O. Navrátil, D. Lizoňová, K. Slonková, L. Mašková, A. Zadražil, D. Sedmidubský, F. Štěpánek
Language English Country Netherlands
Document type Journal Article
- MeSH
- Anti-Bacterial Agents * MeSH
- Escherichia coli MeSH
- Hydrogels chemistry MeSH
- Nanoparticles * chemistry MeSH
- Drug Liberation MeSH
- Publication type
- Journal Article MeSH
Drug depot systems have traditionally relied on the spontaneous dissolution and diffusion of drugs or prodrugs from a reservoir with constant exposure to the surrounding physiological fluids. While this is appropriate for clinical scenarios that require constant plasma concentration of the drug over time, there are also situations where multiple bursts of the drug at well-defined time intervals are preferred. This work presents a drug depot system that enables repeated on-demand release of antibiotics in precise doses, controlled by an external radiofrequency magnetic field. The remotely controlled depot system consists of composite microcapsules with a core-shell structure. The core contains micronized drug particles embedded in a low-melting hydrophobic matrix. The shell is formed by a hydrogel with immobilised magnetic nanoparticles that facilitate local heat dissipation after exposure to a radiofrequency magnetic field. When the melting point of the core material is locally exceeded, the embedded drug particles are mobilised and their surface is exposed to the external aqueous phase. It is shown that drug release can be controlled in an on/off manner by a chosen sequence and duration of radiofrequency pulses. The capacity of the depot system is shown to be significantly higher than that of purely diffusion-controlled systems containing a pre-dissolved drug. The functionality of the depot system is demonstrated in vitro for the specific case of norfloxacin acting on E. coli.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024535
- 003
- CZ-PrNML
- 005
- 20221031100428.0
- 007
- ta
- 008
- 221017s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.colsurfb.2022.112618 $2 doi
- 035 __
- $a (PubMed)35738076
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Navrátil, Ondřej $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 245 10
- $a Antibiotic depot system with radiofrequency controlled drug release / $c O. Navrátil, D. Lizoňová, K. Slonková, L. Mašková, A. Zadražil, D. Sedmidubský, F. Štěpánek
- 520 9_
- $a Drug depot systems have traditionally relied on the spontaneous dissolution and diffusion of drugs or prodrugs from a reservoir with constant exposure to the surrounding physiological fluids. While this is appropriate for clinical scenarios that require constant plasma concentration of the drug over time, there are also situations where multiple bursts of the drug at well-defined time intervals are preferred. This work presents a drug depot system that enables repeated on-demand release of antibiotics in precise doses, controlled by an external radiofrequency magnetic field. The remotely controlled depot system consists of composite microcapsules with a core-shell structure. The core contains micronized drug particles embedded in a low-melting hydrophobic matrix. The shell is formed by a hydrogel with immobilised magnetic nanoparticles that facilitate local heat dissipation after exposure to a radiofrequency magnetic field. When the melting point of the core material is locally exceeded, the embedded drug particles are mobilised and their surface is exposed to the external aqueous phase. It is shown that drug release can be controlled in an on/off manner by a chosen sequence and duration of radiofrequency pulses. The capacity of the depot system is shown to be significantly higher than that of purely diffusion-controlled systems containing a pre-dissolved drug. The functionality of the depot system is demonstrated in vitro for the specific case of norfloxacin acting on E. coli.
- 650 12
- $a antibakteriální látky $7 D000900
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a Escherichia coli $7 D004926
- 650 _2
- $a hydrogely $x chemie $7 D020100
- 650 12
- $a nanočástice $x chemie $7 D053758
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Lizoňová, Denisa $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Slonková, Karolína $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Mašková, Lucie $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Zadražil, Aleš $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Sedmidubský, David $u Department of Inorganic Chemistry, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address: Frantisek.Stepanek@vscht.cz
- 773 0_
- $w MED00180202 $t Colloids and surfaces. B, Biointerfaces $x 1873-4367 $g Roč. 217, č. - (2022), s. 112618
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35738076 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100426 $b ABA008
- 999 __
- $a ok $b bmc $g 1854322 $s 1175825
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 217 $c - $d 112618 $e 20220607 $i 1873-4367 $m Colloids and surfaces. B, Biointerfaces $n Colloids surf., B Biointerfaces $x MED00180202
- LZP __
- $a Pubmed-20221017